Compare Eversource Energy (D/B/A) Common Stock (ES) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eversource Energy (D/B/A) Common Stock vs Neurocrine Biosciences Inc — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $66.63 (market cap $24.77B), while Neurocrine Biosciences Inc trades at $135.83 (market cap $14.37B). The key difference: Eversource Energy (D/B/A) Common Stock is the larger of the two by market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.79% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and Neurocrine Biosciences Inc for 24 Days on average.
| ES | NBIX | |
|---|---|---|
Market Cap | $24.77B | $14.37B |
Volume | 3,738,127 | 1,081,559 |
Sector | Utilities | Health |
52-Week High | $76.21 | $185.50 |
52-Week Low | $63.28 | $123.10 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $54.84B | $14.38B |
Dividend Yield | 4.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% over 24 hours amid a broader bearish technical signal, though key moving averages and oscillators show mixed signals. Fundamentally, the company demonstrates robust health with a 97.91% gross profit margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 against a $1.85 expectation. Recent news highlights pipeline advancements, including presentations on Prader-Willi syndrome research and executive appointments, supporting long-term growth narratives beyond its flagship product INGREZZA.
The investment outlook for NBIX is positive, driven by strong analyst consensus with a $204.18 price target and 86.49% buy ratings, reflecting confidence in revenue growth and pipeline diversification. Key risks include execution challenges in commercializing new products and potential pricing pressures on INGREZZA post-2029. Investors should weigh the company's high profitability and cash flow generation against these sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
